Biomarkers of the metabolic syndrome and breast cancer prognosis

Qiu Li Zhu, Wang Hong Xu, Meng Hua Tao

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


In spite of its public health importance, our understanding of the mechanisms of breast carcinogenesis and progress is still evolving. The metabolic syndrome (MS) is a constellation of biochemical abnormalities including visceral adiposity, hyperglycemia, hyperinsulinemia, dyslipidemia and high blood pressure. The components of the MS have all been related to late-stage disease and even to a poor prognosis of breast cancer through multiple interacting mechanisms. In this review, we aim to present a summary of recent advances in the understanding of the contribution of the MS to breast cancer with the emphasis on the role of biomarkers of the MS in the prognosis of breast cancer.

Original languageEnglish
Pages (from-to)721-739
Number of pages19
Issue number2
StatePublished - Jun 2010


  • Biomarkers
  • Breast cancer
  • Epidemiology
  • Metabolic syndrome
  • Prognosis


Dive into the research topics of 'Biomarkers of the metabolic syndrome and breast cancer prognosis'. Together they form a unique fingerprint.

Cite this